The CD163+ TAMs in the primary NSCLC and brain metastases were 18.506 ± 20.242 and 21.471 ± 33.909 per high-power field (P = 0.654, a paired Student’s t-test). This evidence concerns the gene CD163 and non-small cell lung carcinoma.